{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Podcast","title":"Long-term efficacy and safety of betibeglogene autotemcel for β-thalassemia","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/b9b05532\"></iframe>","width":"100%","height":180,"duration":784,"description":"In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Alexis Thompson, former ASH president, on her latest article published in Blood. Dr. Thompson discusses \"Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.\" She explains transfusion-dependent β-thalassemia (TDT) requires rigorous, lifelong transfusion therapy and iron chelation to manage iron overload. Dr. Kwiatkowski and colleagues discuss the long-term efficacy and safety of this gene therapy in 63 patients with TDT, documenting sustained transfusion independence for up to 10 years and a safety profile consistent with that of myeloablative autologous transplantation.","thumbnail_url":"https://img.transistorcdn.com/v7MGyoJEM-ebFBYi5VpSwDRF3QY3zbinfCyyOAH1TGk/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kY2Q4/YzJhZmMwODBjOWRi/YTNhN2Y1NWJkMzMw/NTBjZi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}